Back to Studies

P1076 / Impact of Oral Alendronate Therapy on BMD in HIV-Infected Children/Adolescents

Impact of Oral Alendronate Therapy on Bone Mineral Density in HIV-Infected Children and Adolescents with Low Bone Mineral Density at Baseline

Study Status


DAIDS Number


IND Number


Clinical Trials Link


P1076 is randomized, placebo-controlled, double blind pilot study of oral alendronate therapy in HIV-infected participants ≥ 11 to < 25 years of age not on antiretroviral treatment or on stable antiretroviral treatment and with low bone mineral density.  The study is designed to estimate and compare changes from pre-treatment levels in BMD of the lumbar spine and to assess the safety of alendronate.

Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...